Show simple item record

Functional roles of the factor VIII B domain

dc.contributor.authorPipe, Steven W.en_US
dc.date.accessioned2010-06-01T21:45:28Z
dc.date.available2010-06-01T21:45:28Z
dc.date.issued2009-11en_US
dc.identifier.citationPIPE, S. W. (2009). "Functional roles of the factor VIII B domain." Haemophilia 15(6): 1187-1196. <http://hdl.handle.net/2027.42/74800>en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74800
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19473417&dopt=citationen_US
dc.format.extent307500 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2009 Blackwell Publishing Ltden_US
dc.subject.otherB Domainen_US
dc.subject.otherBlood Coagulation Factorsen_US
dc.subject.otherFactor VIIIen_US
dc.subject.otherHaemophilia Aen_US
dc.subject.otherProtein Engineeringen_US
dc.subject.otherRecombinant Proteinsen_US
dc.titleFunctional roles of the factor VIII B domainen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid19473417en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74800/1/j.1365-2516.2009.02026.x.pdf
dc.identifier.doi10.1111/j.1365-2516.2009.02026.xen_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceGitschier J, Wood WI, Goralka TM et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326 – 30.en_US
dc.identifier.citedreferenceVehar GA, Keyt B, Eaton D et al. Structure of human factor VIII. Nature 1984; 312: 337 – 42.en_US
dc.identifier.citedreferenceKaufman RJ. Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology. Ann Hematol 1991; 63: 155 – 65.en_US
dc.identifier.citedreferenceLenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983 – 96.en_US
dc.identifier.citedreferenceWang W, Wang YJ, Kelner DN. Coagulation factor VIII: structure and stability. Int J Pharm 2003; 259: 1 – 15.en_US
dc.identifier.citedreferenceToole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approx. equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939 – 42.en_US
dc.identifier.citedreferenceFay PJ. Factor VIII structure and function. Thromb Haemost 1993; 70: 63 – 7.en_US
dc.identifier.citedreferenceEaton DL, Wood WI, Eaton D et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 1986; 25: 8343 – 7.en_US
dc.identifier.citedreferenceMeulien P, Faure T, Mischler F et al. A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII. Protein Eng 1988; 2: 301 – 6.en_US
dc.identifier.citedreferencePittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925 – 35.en_US
dc.identifier.citedreferencePittman DD, Marquette KA, Kaufman RJ. Role of the B domain for factor VIII and factor V expression and function. Blood 1994; 84: 4214 – 25.en_US
dc.identifier.citedreferenceLi X, Gabriel DA. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding. Biochemistry 1997; 36: 10760 – 7.en_US
dc.identifier.citedreferencePipe SW, Morris JA, Shah J, Kaufman RJ. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem 1998; 273: 8537 – 44.en_US
dc.identifier.citedreferenceMoussalli M, Pipe SW, Hauri HP, Nichols WC, Ginsburg D, Kaufman RJ. Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII. J Biol Chem 1999; 274: 32539 – 42.en_US
dc.identifier.citedreferenceCunningham MA, Pipe SW, Zhang B, Hauri HP, Ginsburg D, Kaufman RJ. LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost 2003; 1: 2360 – 7.en_US
dc.identifier.citedreferenceMiao HZ, Sirachainan N, Palmer L et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103: 3412 – 9.en_US
dc.identifier.citedreferenceBovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost 2005; 3: 1257 – 65.en_US
dc.identifier.citedreferencePipe SW, Miao HZ, Kucab P, McVey JH, Kaufman RJ. The secretion efficiency of Factor VIII can be regulated by the size and oligosaccharide content of the B domain. Blood 2005; 106: Abstract # 687.en_US
dc.identifier.citedreferenceZhang B, Kaufman RJ, Ginsburg D. LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J Biol Chem 2005; 280: 25881 – 6.en_US
dc.identifier.citedreferenceKhrenov AV, Ananyeva NM, Saenko EL. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X. Blood Coagul Fibrinolysis 2006; 17: 379 – 88.en_US
dc.identifier.citedreferenceKaufman RJ, Pipe SW. Regulation of factor VIII expression and activity by von Willebrand factor. Thromb Haemost 1999; 82: 201 – 8.en_US
dc.identifier.citedreferenceHerlitschka SE, Schlokat U, Falkner FG, Dorner F. High expression of a B-domain deleted factor VIII gene in a human hepatic cell line. J Biotechnol 1998; 61: 165 – 73.en_US
dc.identifier.citedreferenceKaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M. Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 1997; 8 ( Suppl 2 ): S3 – 14.en_US
dc.identifier.citedreferenceLynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259 – 72.en_US
dc.identifier.citedreferenceHoeben RC, Fallaux FJ, Cramer SJ et al. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995; 85: 2447 – 54.en_US
dc.identifier.citedreferenceDorner AJ, Bole DG, Kaufman RJ. The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol 1987; 105: 2665 – 74.en_US
dc.identifier.citedreferenceEllgaard L, Helenius A. Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 2003; 4: 181 – 91.en_US
dc.identifier.citedreferenceZhang B, McGee B, Yamaoka JS et al. Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood 2006; 107: 1903 – 7.en_US
dc.identifier.citedreferenceFowler WE, Fay PJ, Arvan DS, Marder VJ. Electron microscopy of human factor V and factor VIII: correlation of morphology with domain structure and localization of factor V activation fragments. Proc Natl Acad Sci USA 1990; 87: 7648 – 52.en_US
dc.identifier.citedreferenceBihoreau N, Paolantonacci P, Bardelle C et al. Structural and functional characterization of Factor VIII-delta II, a new recombinant factor VIII lacking most of the B-domain. Biochem J 1991; 277: 23 – 31.en_US
dc.identifier.citedreferenceMarquette KA, Pittman DD, Kaufman RJ. A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem 1995; 270: 10297 – 303.en_US
dc.identifier.citedreferenceFay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986; 871: 268 – 78.en_US
dc.identifier.citedreferenceJankowski MA, Patel H, Rouse JC, Marzilli LA, Weston SB, Sharpe PJ. Defining ‘full-length’ recombinant factor VIII: a comparative structural analysis. Haemophilia 2007; 13: 30 – 7.en_US
dc.identifier.citedreferencePittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci USA 1988; 85: 2429 – 33.en_US
dc.identifier.citedreferenceNewell JL, Fay PJ. Proteolysis at Arg740 facilitates subsequent bond cleavages during thrombin-catalyzed activation of factor VIII. J Biol Chem 2007; 282: 25367 – 75.en_US
dc.identifier.citedreferenceLind P, Larsson K, Spira J et al. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur J Biochem 1995; 232: 19 – 27.en_US
dc.identifier.citedreferenceSandberg H, Almstedt A, Brandt J et al. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 2001; 85: 93 – 100.en_US
dc.identifier.citedreferenceFay PJ, Chavin SI, Malone JE, Schroeder D, Young FE, Marder VJ. The effect of carbohydrate depletion on procoagulant activity and in vivo survival of highly purified human factor VIII. Biochim Biophys Acta 1984; 800: 152 – 8.en_US
dc.identifier.citedreferenceBardelle C, Furie B, Furie BC, Gilbert GE. Membrane binding kinetics of factor VIII indicate a complex binding process. J Biol Chem 1993; 268: 8815 – 24.en_US
dc.identifier.citedreferenceGruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis—a meta-analysis. Haemophilia 2003; 9: 251 – 60.en_US
dc.identifier.citedreferenceBovenschen N, Boertjes RC, van Stempvoort G et al. Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J Biol Chem 2003; 278: 9370 – 7.en_US
dc.identifier.citedreferenceBovenschen N, van Stempvoort G, Voorberg J, Mertens K, Meijer AB. Proteolytic cleavage of factor VIII heavy chain is required to expose the binding-site for low-density lipoprotein receptor-related protein within the A2 domain. J Thromb Haemost 2006; 4: 1487 – 93.en_US
dc.identifier.citedreferenceBovenschen N, Herz J, Grimbergen JM et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood 2003; 101: 3933 – 9.en_US
dc.identifier.citedreferenceKessler CM, Gill JC, White GC II et al. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia 2005; 11: 84 – 91.en_US
dc.identifier.citedreferencedi Paola J, Smith MP, Klamroth R et al. ReFacto ® and Advate ®: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 2007; 13: 124 – 30.en_US
dc.identifier.citedreferenceMikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646 – 50.en_US
dc.identifier.citedreferenceMikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 13 – 23.en_US
dc.identifier.citedreferenceMikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin Thromb Hemost 2002; 28: 257 – 64.en_US
dc.identifier.citedreferencePurohit VS, Ramani K, Kashi RS, Durrani MJ, Kreiger TJ, Balasubramanian SV. Topology of factor VIII bound to phosphatidylserine-containing model membranes. Biochim Biophys Acta 2003; 1617: 31 – 8.en_US
dc.identifier.citedreferenceHubbard AR, Weller LJ, Bevan SA. Activation profiles of factor VIII in concentrates reflect one-stage/chromogenic potency discrepancies. Br J Haematol 2002; 117: 957 – 60.en_US
dc.identifier.citedreferenceHubbard AR, Sands D, Sandberg E, Seitz R, Barrowcliffe TW. A multi-centre collaborative study on the potency estimation of ReFacto. Thromb Haemost 2003; 90: 1088 – 93.en_US
dc.identifier.citedreferenceSmith MP, Giangrande P, Pollman H, Littlewood R, Kollmer C, Feingold J. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005; 11: 444 – 51.en_US
dc.identifier.citedreferenceKoster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152 – 5.en_US
dc.identifier.citedreferenceBank I, Libourel EJ, Middeldorp S et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79 – 84.en_US
dc.identifier.citedreferenceKyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457 – 62.en_US
dc.identifier.citedreferenceViel KR, Machiah DK, Warren DM et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 2007; 109: 3713 – 24.en_US
dc.identifier.citedreferenceEl-Maarri O, Schwalbach J, Herbiniaux U, Hanfland P, Oldenburg J. Functional analysis of the Factor VIII B domain. In: Scharrer I, Schramm W, eds. 34th Hemophilia Symposium Hamburg 2003, 2005: 334 – 7.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.